Abstract:Alport syndrome (AS) is a hereditary kidney disease associated with proteinuria, hematuria and progressive kidney failure. It is characterized by a defective glomerular basement membrane caused by mutations in type IV collagen genes COL4A3/A4/A5 which result in defective type IV collagen α3, α4, or α5 chains, respectively. Alport syndrome has three different patterns of inheritance: X-linked, autosomal and digenic. In a study of CKD of unknown etiology type IV collagen gene mutations accounted for the majority of the cases of hereditary glomerulopathies which suggests that AS is often underrecognized. The natural history and prognosis in patients with AS is variable and is determined by genetics and environmental factors. At present, no preventive or curative therapies exist for AS. Current treatment includes the use of renin-angiotensin-aldosterone system inhibitors which slow progression of kidney disease and prolong life expectancy. Ramipril was found in retrospective studies to delay the onset of ESKD and was recently demonstrated to be safe and effective in children and adolescents, supporting that early initiation of Renin Angiotensin Aldosterone System (RAAS) blockade is very important. Mineralocorticoid receptor blockers might be favorable for patients who develop "aldosterone breakthrough." While the DAPA-CKD trial suggests a beneficial effect of SGLT2 inhibitors in CKD of non-metabolic origin, only a handful of patients had Alport in this cohort, and therefore conclusions can't be extrapolated for the treatment of AS with SGLT2 inhibitors. Advances in our understanding on the pathogenesis of Alport syndrome has culminated in the development of innovative therapeutic approaches that are currently under investigation. We will provide a brief overview of novel therapeutic targets to prevent progression of kidney disease in AS. Our review will include bardoxolone methyl, an oral NRf2 activator; lademirsen, an anti-miRNA-21 molecule; sparsentan, dual endothelin type A receptor (ETAR) and angiotensin 1 receptor inhibitor; atrasentan, oral selective ETAR inhibitor; lipid-modifying agents, including cholesterol efflux transporter ATP-binding cassette A1 (ABCA1) inducers, discoidin domain receptor 1 (DDR1) inhibitors and osteopontin blocking agents; the antimalarial drug hydroxychloroquine; the antiglycemic drug metformin and the active vitamin D analog paricalcitol. Future genomic therapeutic strategies such as chaperone therapy, genome editing and stem cell therapy will also be discussed.

Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome

Cyclosporin A Combination with Angiotensin-Converting Enzyme Inhibitor in Treatment of Alport's Syndrome

Drugs Controlling Proteinuria of Patients with Alport Syndrome

Dissecting the genotype-phenotype correlation of <i>COL4A5</i> gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome

Genotype–phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome

Outcome of Renal Transplantation in Patients with Alport Syndrome: Report of 11 Cases

Clinical, histological and molecular characteristics of Alport syndrome in Chinese children

Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children

Effectiveness of renin-angiotensin-aldosterone system blockers in patients with Alport syndrome: a systematic review and meta-analysis.

Novel Therapies for Alport Syndrome

Long-term Follow-Up of an Alport Syndrome Patient with a Novel Mutation of COL4A5.

Acei/Arb Therapy for Iga Nephropathy: A Meta Analysis of Randomised Controlled Trials

Reassuring pregnancy outcomes in women with mild COL4A3-5 related disease (Alport Syndrome) as the genetic type of disease can aid personalized counseling.

[Clinical and Pathological Study of 47 Cases with Alport Syndrome].

[Features of Clinical Phenotype and Genotype in Alport Syndrome: a Monocentric Study].

Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative

Short-term effects of tacrilimus in patients with Alport syndrome

Pregnancy in women with autosomal recessive Alport syndrome caused by novel compound heterozygous mutations of COL4A3 gene: Two cases reports

Human umbilical cord mesenchymal stem cell therapy for renal dysfunction in Alport syndrome: protocol for an open-label, single-arm trial in China

Combination Therapy An Ace Inhibitor And An Angiotensin Receptor Blocker For Iga Nephropathy: A Meta-Analysis

Alport syndrome: Expanding diagnosis and treatment